FDA Approves Talvey (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple MyelomaHORSHAM, Pa., Aug. 10, 2023 – The...
Accelerated US approval of a first-in-class bispecific antibody (BsAb) therapy offers a new option for a difficult-to-treat blood cancer.
The US Food and Drug Administration...
It was once a common assumption within the cannabis community that plant cannabinoids aren’t “activated” or useful until they are “decarbed” — short for decarboxylated...
A viral infection that affects the liver and can cause both acute and chronic disease, hepatitis B affects around 296 million people worldwide, and,...
A major player in the machinery, electronics and telecommunications market, South Korea’s growing biotech industry has made headlines over the past few years. Home...
Project CBD recently reported on studies indicating that cannabis terpenes — the compounds that give the plant its robust and distinctive smell — activate...
Highlights
Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with...
